Home » Authors » Brady Huggett

Articles by Brady Huggett

Cypress Gains Additional Rights In Pierre Fabre Milnacipran Deal

June 10, 2003

By Brady Huggett

Restructured EpiGenesis Raises $23M To Fund Asthma Product

June 9, 2003

By Brady Huggett

Restructured EpiGenesis Raises $23M To Fund Asthma Product

June 9, 2003

By Brady Huggett

Isis, Lilly Rework Agreement For Affinitak Manufacturing

June 6, 2003

By Brady Huggett

Discovery Labs' Surfaxin Support Trial Provides Positive Early Data

June 6, 2003

By Brady Huggett

Discovery Labs' Surfaxin Support Trial Provides Positive Early Data

June 6, 2003

By Brady Huggett

Isis, Lilly Rework Agreement For Affinitak Manufacturing

June 6, 2003

By Brady Huggett

Listing On London's AIM Market Poses Challenges For U.S. Firms

June 2, 2003

By Brady Huggett

Listing On London's AIM Market Poses Challenges For U.S. Firms

June 2, 2003

By Brady Huggett

LSE Rule Change Meant To Spark More Foreign Listings In London

May 30, 2003

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...